Metabolomic profile of human plasma associated with a comparative drug treatment time course study of two platelet aggregation inhibitors

Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despite advances in pharmacological therapy. To monitor their differential response to treatment, we performed untargeted plasma metabolomics on 175 patients from the PLATelet inhibition and patient Outcomes (PLATO) trial, treated with ticagrelor and clopidogrel, two common P2Y12 inhibitors. We identified a signature that discriminates patients, which involves polyunsaturated fatty acids (PUFA), and particularly the omega-3 fatty acids docosahexaenoate and eicosapentaenoate. The present dataset comprises a total of 280 compounds of known identity (named biochemicals). Metabolon received 360 human serum samples. Following receipt, samples were inventoried, and immediately stored at -80 C. At the time of analysis samples were extracted and prepared for analysis using Metabolon’s standard solvent extraction method. The extracted samples were split into equal parts for analysis on the GC/MS and LC/MS/MS platforms. To reduce biases due to highly variable metabolites’ range, raw concentrations were subjected to auto-scaling and were log transformed. Raw Metabolon dataset is available upon request. Detailed metadata (including run days and batch groups) for each sample is also provided